Q2 FY2025 · Press release
Krystal Biotech Announces First Patient Dosed in Phase 1_2 Trial of KB801 for the Treatment of Neurotrophic Keratitis · July 9, 2025 · 2 pages
Read Krystal Biotech, Inc.'s results firsthand
Preview this press release
Create a free account to start reading
Full documents are included with Professional